<DOC>
	<DOCNO>NCT01150682</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tissue patient cancer laboratory may help doctor identify learn biomarkers related cancer . PURPOSE : This research study study role biomarkers endometrial cancer recurrence sample patient stage II , stage III , stage IV endometrial cancer .</brief_summary>
	<brief_title>Role Biomarkers Endometrial Cancer Recurrence Samples From Patients With Stage II , Stage III , Stage IV Endometrial Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To investigate association endometrioid adenocarcinoma ( EA ) recurrence pre-operative serum level insulin , total free insulin-like growth factor-I ( IGF-I ) , IGF-II , insulin-like growth factor-binding protein-1 ( IGFBP-1 ) IGFB-3 , estradiol , estrone , progesterone , sex hormone-binding globulin ( SHBG ) sample patient stage II-IV endometrial cancer evaluate GOG-0210 . - To study association EA recurrence pre-treatment tumor expression IGF-I , IGF-II , IGFBP-1 -3 mRNA sample patient . - To study association EA recurrence pre-treatment tumor expression insulin receptor , IGF-I receptor , estrogen receptor , progesterone receptor sample patient . - To measure correlation serum ( protein ) tissue ( mRNA ) level IGF-I , IGF-II , IGFBP-1 -3 sample patient EA participant without cancer . OUTLINE : Banked serum tumor tissue sample analyze level insulin , total free insulin-like growth factor ( IGF-I ) , IGF-II , IGFBP-1 IGFBP-3 , estradiol , estrone , progesterone sex hormone-binding globulin ( SHBG ) ; expression IGF-I , IGF-II , IGFBP-1 IGFBP -3 mRNA ; expression insulin receptor , IGF-I receptor , estrogen receptor , progesterone receptor RT-PCR , IHC , ELISA . Banked non-cancerous endometrial tissue fast serum sample control also analyze IGF-I , IGF-II , IGFBP-1 , IGFBP-3 compare result endometrial adenocarcinoma ( EA ) sample . Clinical information associate EA sample ( i.e. , age , BMI , performance status , race , ethnicity , tumor stage , size , histology grade , surgical compliance type post surgical adjuvant therapy , overall survival , recurrence-free survival , site first recurrence , biomarker value expression ) also collect . PROJECTED ACCRUAL : A total 815 patient specimen 50 control specimen accrue study .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm endometrioid endometrial cancer Stage IIIV disease Patients eligible evaluate GOG0210 , Molecular Staging Endometrial Cancer clinical trial , meeting follow criterion : Allowed specimen clinical data collect part participation Have sufficient highquality freeze primary tumor , formalinfixed paraffinembedded ( FFPE ) primary tumor , and/or preoperative serum test available Patients underwent surgical staging specify GOG0210 protocol describe GOG Surgical Manual Protocol , include follow procedure : Hysterectomy Bilateral oophorectomy Washings well pelvic lymphadenectomy paraaortic lymphadenectomy Noncancerous endometrial tissue fast serum control sample meet follow criterion ( control ) : Underwent hysterectomy treat uterine prolapse Albert Einstein Hospital Montefiore Medical Center , Bronx , NY No uterine fibroid prior cancer PATIENT CHARACTERISTICS : Postmenopausal patient control PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>endometrial adenocarcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>endometrial adenosquamous cell carcinoma</keyword>
	<keyword>endometrial clear cell carcinoma</keyword>
	<keyword>endometrial papillary serous carcinoma</keyword>
</DOC>